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Up to date, preclinical screening for new antiepileptic substances is performed by a
combination of different in vivo models of acute seizures, for which large numbers
of animals are necessary. So far, little attention has been paid to in vitro models,
which are also able to detect antiepileptic efficacy and in principle could likewise serve
for exploratory preclinical screening. One of the established in vitro models of acute
seizures is the 4-aminopyridine (4-AP) model. Previous studies have shown that the 4-
AP model is capable to recapitulate the antiepileptic efficacy of standard antiepileptic
drugs (AEDs) such as valproate or carbamazepine. Here, we employed a dual
methodological approach using electrophysiology and optical imaging to systematically
test the antiepileptic efficacy of three new-generation AEDs with distinct mechanisms
of action (lacosamide, zonisamide, and levetiracetam). We found that frequency of
4-AP induced seizure like events (SLE) was the most sensitive parameter to detect
dose-dependent antiepileptic effects in these compounds. Specifically, levetiracetam
reduced SLE frequency while lacosamide and zonisamide at higher doses completely
blocked SLE incidence. Analysis of the intrinsic optical signal additionally revealed a
subiculum-specific reduction of the area involved in the propagation of ictal activity
when lacosamide or zonisamide were administered. Taken together, our data adds
some evidence that acute seizure models in vitro are in principle capable to detect
antiepileptic effects across different mechanisms of action with efficacy similar to acute
models in vivo. Further studies with negative controls, e.g., penicillin as a proconvulsant,
and other clinically relevant AEDs are needed to determine if this acute in vitro model
might be useful as exploratory screening tool. In view of the increasing sensitivity toward
animal welfare, an affective in vitro model may help to reduce the number of laboratory
animals deployed in burdening in vivo experiments and to preselect substances for
subsequent testing in time- and cost-laborious models of chronic epilepsy.
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INTRODUCTION
Epilepsy is a major neurological disorder affecting ∼1% of the population (Hirtz et al., 2007).
Treatment of epilepsy is focused on reducing seizure burden, mainly achieved by antiepileptic
drugs (AEDs). Driven by a significant pharmacoresistance rate of about 30% (Chen et al.,
2018) and major adverse effects of classical AEDs like phenobarbital or carbamazepine
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(Perucca and Gilliam, 2012), several drug screening programs for
detection of new AEDs were established in the last three to four
decades (Löscher and Schmidt, 2011).
In these programs, initial screening of compounds with
potential antiepileptic properties was mainly based on two
acute in vivo seizure models: the maximal electroshock (MES)
and the pentylenetetrazole model (PTZ). In the MES model
introduced by Putnam and Merritt (1937), seizures are induced
electrically by extracranial or corneal stimulation; MES-induced
seizures are mainly sensitive to sodium channel blockers like
carbamazepine or lamotrigine (Barton et al., 2001). The PTZ
model, on the contrary, induces seizures chemically by blockade
of GABA-A receptors (Löscher, 2011). Consequently, PTZ-
induced seizures are rather sensitive to drugs acting on GABA-
A receptors such as valproate or benzodiazepines (Everett and
Richards, 1944; Barton et al., 2001). Although both models act
in a complementary fashion, their combined ability to detect
novel AEDs still has its weaknesses. This is best exemplified
by levetiracetam, an AED introduced at the beginning of
21st century and widely used in clinical practice to date.
Levetiracetam failed to be effective against seizures in both
the MES and the PTZ models, but was effective against
psychomotor seizures induced by 6 Hz corneal stimulation,
another electrical model of acute seizures (Brown et al., 1953;
Barton et al., 2001). Another important limitation is that
in vivo models of acute seizures are implemented in naive
brains which does not reflect the clinical setting in patients
with chronic epilepsy characterized by and defined as an
“enduring predisposition to generate epileptic seizures” (Fisher
et al., 2014). Therefore in a second step, chronic epilepsy
models, e.g., based on chemically induced status epilepticus
by kainic acid or pilocarpine, and subsequent development of
spontaneous recurrent seizures, are employed to evaluate the
antiepileptic potential of novel substances such as levetiracetam
and lacosamide (Glien et al., 2002; Behr et al., 2015; Klein et al.,
2015; West et al., 2018).
In summary, the use of multiple and complementary seizure
models seems to be paramount for detection of novel AEDs.
However, combining several in vivo models comes with the
cost of high number of used animals, and, specifically in case
of chronic models, increased animal suffering. This stands in
contrast to the 3R principle (reduce, refine, replace) for more
ethical use of animals in testing (Russel and Burch, 1959).
In vitro models offer the advantage of avoiding animal
suffering and of performing several experiments on brain slices
from one animal at the same time point. In case of acute seizure
models in vitro, a plethora of different models has been in use to
induce seizure-like events (SLEs), including electrical stimulation
(Stasheff et al., 1985, 1989), alteration of the extracellular ion
composition (Yaari et al., 1983; Konnerth et al., 1986; Mody
et al., 1987; Agopyan and Avoli, 1988; Albrecht et al., 1989;
Tancredi et al., 1990), and finally pharmacological intervention
(Voskuyl and Albus, 1985; Chesnut and Swann, 1988). Some
in vitro models were postulated to reflect pharmacoresistance as
epileptiform activity in these specific models was not responsive
toward standard antiepileptic treatment (Brückner et al., 1999;
Albus et al., 2008).
In the present study, we aimed to assess antiepileptic
properties across different substance classes using a well-
established in vitro acute seizure model in rodent brain tissue.
A secondary aim was to contribute to the question if this in vitro
model has the potential to be a valid tool for discovery of
AEDs. To that end, we focused on the 4-aminopyridone (4-
AP) model of acute seizures. This model has the advantage of
stable and spontaneous occurrence of SLEs and a low rate of
spreading depolarizations when compared to other models, i.e.,
the low Mg2+ model or electrical stimulation. In previous work,
standard AEDs including carbamazepine, topiramate, phenytoin
and valproic acid have been investigated in the 4-AP model
in vivo and in vitro (Fueta and Avoli, 1992; Yamaguchi and
Rogawski, 1992; Brückner and Heinemann, 2000; D’Antuono
et al., 2010). Here, we specifically focused on new-generation
AEDs with distinct mechanisms of action. By using a combined
electrophysiological and optical approach, we chose to investigate
effects of lacosamide (LAC), a sodium channel blocker (Lees
et al., 2006; Rogawski et al., 2015), zonisamide (ZNS), for which
multiple mechanisms including inhibition of voltage-sensitive
T-type calcium currents have been described (Leppik, 2004;
Thöne et al., 2008), and finally levetiracetam (LEV), which acts
on the synaptic vesicle protein SV2A (Bajjalieh et al., 1994;
Lynch et al., 2004).
MATERIALS AND METHODS
All experimental procedures were conducted in accordance with
the German Animal Welfare Act and the European Directive
2010/63/EU for animal experiments, and with approval of
the Institutional Animal Welfare Officer and the responsible




All experiments were performed in hippocampal-entorhinal
slices from adult, 7–11 week-old, Wistar Han rats (200–350 g).
The slices were prepared as described previously (Buchheim
et al., 1999) with several modifications. In brief, all animals
were decapitated under deep isoflurane anesthesia. The brains
were quickly removed and then stored in ice cold artificial
cerebrospinal fluid (ACSF) which contained (in mM): NaCl
129.0, KCl 3.0, MgSO2 1.8, CaCl2 1.6, NaH2PO4 1.25, NaHCO3
21.0, and glucose 10.0 (pH 7.4), and was continuously oxygenated
with carbogen (95% O2, 5% CO2). Horizontal brain slices
(400 µm) were cut using a vibratome (752M Vibroslice,
Campden Instruments Ltd., Loughborough, United Kingdom).
Slices enclosed the temporal (TC) and perirhinal cortices
(PC), the entorhinal cortex (EC), the subiculum (SUB), the
dentate gyrus (DG), and the ventral hippocampus. After
preparation, slices were placed in a Haas-type interface chamber
(Haas et al., 1979) and were continuously perfused (1.5–
2.0 ml/min) with prewarmed (35◦C) and carbogenated ACSF.
In addition, warmed, humified carbogen was directed over
the slice surface. Slices were allowed to recover at least
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1 h before recordings started on a transparent membrane
(0.4 µm Millicell culture plate inserts; Millipore, Bedford,
MA, United States).
Electrophysiological Recordings
Extracellular local field potential (LFP) recordings were
carried out with a glass electrode filled with 150 mM NaCl
(electrode resistance 1–2 M). Signals were acquired with
custom-made amplifiers (10×) connected to an AD converter
(Micro 1401 mk II, Cambridge Electronic Design Limited,
Cambridge, United Kingdom). Data were recorded and
analyzed using Spike2 and Signal (versions 7.00 and 3.07,
respectively, Cambridge Electronic Design Limited, Cambridge,
United Kingdom) and Matlab (R2014b, MathWorks, Natick,
MA, United States) software.
Before assessment of drug effects, slice viability was tested by
stimulation of Schaffer collaterals (150 µs, 3–5 mV DC) with a
bipolar electrode placed in the stratum radiatum of the distal
CA3 area and subsequent recording of population spikes in the
CA1 area. Only slices with population spike amplitudes of>2 mV
were accepted for further experiments. After viability testing, the
stimulation electrode was removed and the recording electrode
was placed in the deep layers (IV and V) of the lateral EC.
Seizure like events (SLE) were induced by application of 4-
AP (100 µM), a non-selective potassium channel blocker (Rudy,
1988) and a potent proconvulsant compound in the limbic system
in vitro (Perreault and Avoli, 1991; Yonekawa et al., 1995; Avoli
et al., 1996). 4-AP application resulted in occurrence of SLEs that
were identified electrographically using the following criteria: (1)
decrease in field potential of at least 0.5 mV, (2) duration of
the field potential shift of at least 10 s, and (3) superimposition
by ripple-like discharges. Slices that did not exhibit SLEs within
45 min of perfusion with 4-AP were excluded.
Intrinsic Optical Imaging
To monitor spatial propagation of SLEs, we recorded intrinsic
optical signals (IOS), which were simultaneously acquired
with electrophysiological recordings. Using this methodological
approach, the entire slice can be examined non-invasively for
onset and propagation of ictal epileptiform activity (Weissinger
et al., 2000; Holtkamp et al., 2011). For this purpose, slices
were positioned above a curved acrylic glass rod (∅ 8 mm)
and then homogeneously illuminated from below by a halogen
lamp (KL 1500, Schott, Wiesbaden, Germany). The slices were
visualized via an upright binocular light microscope (MS 5, Leica,
Bensheim, Germany) and a 2.5× objective (total magnification
12.5×). Video images were acquired by a monocular phototube
(Leica, Bensheim, Germany), a CCD camera (8 bit, Sanyo, Osaka,
Japan) and an in-house acquisition software. Video signals were
converted at a 10 MHz ratio into 320 × 240 pixel images
employing a frame-grabber board (pciGrabber-4plus, Phytec,
Mainz, Germany). Data were stored on a hard disk of a personal
computer for later processing.
All images were processed and analyzed oﬄine using in-house
ImageJ/FIJI macros and Matlab software. Images were not saved
continuously, but only when triggered by the experimenter in
case a SLE became apparent in the electrophysiological recording.
Using a circular data buffer, the first image was captured 5–
10 s before the electrical onset of the SLE and the recording
continued for 50–180 s depending on the duration of the SLE in
the electrophysiological recording.
The time course of light transmittance was calculated for each
SLE separately as difference (1T) in light transmittance between
a given image and the control image (mean of the first 20 images
in each series, recorded before start of ictal event), and expressed
as percentage of the control image intensity (1T/T). Results
from specific areas (SUB, EC, PC, and TC) were calculated using
squared regions of interest (20 × 20 pixels) placed over a given
area. During SLEs,1T/T typically ranged from 0.4 to 4% whereas
noise level fluctuations were below 0.1% within a single region
of interest (ROI). For calculation of the SLE area, every pixel
within a given anatomical region that reached at least 1% 1T/T
in >9 subsequent images during one SLE was considered to be
involved in this SLE. The SLE area was calculated for each region
separately and expressed as percentage of the total area for a given
anatomical region.
Apart from defined areas of interest, IOS changes over
time and space allowed evaluation of SLE onset regions and
propagation patterns across the whole slice area. For this purpose,
IOS intensity was pseudo color-coded and displayed as videos.
Assessment of AED Effects
Upon establishment of stable SLE amplitude and incidence rate,
which occurred after wash-in of 4-AP for ∼40 min, AEDs to be
tested were washed in for the duration of 40–60 min. The drug
period was followed by a wash-out period of 40–60 min before
finishing the experiment. For an overview of the experimental
protocol, see Figure 1A. For each phase (baseline, intervention,
and wash-out), three to five SLEs were taken for analysis at the
end of the respective phase to ensure that possible effects have
reached a plateau. Three different concentrations chosen from
previous literature were applied for each AED tested: lacosamide:
10, 33, and 100 µM (Lees et al., 2006; May et al., 2015);
zonisamide: 33, 100, and 300 µM (Yamaguchi and Rogawski,
1992; Ueda et al., 2003; Thöne et al., 2008); levetiracetam: 33,
100, and 300 µM (Löscher and Hönack, 1993; Margineanu and
Klitgaard, 2000; Boido et al., 2010).
Data Analysis and Presentation
Data were analyzed and figures were processed with R3.5.1
(Vienna, Austria; R Core Team, 2016) and Inkscape 0.92.3
(The Inkscape Project1). The responder rate was defined
as the ratio of slices with a reduction of SLE frequency
of ≥50% during intervention compared to all investigated
slices. For comparison between baseline, intervention/second
hour and wash-out/third hour, linear mixed-effects models
for repeated measurements were fitted followed by ANOVA
table calculation (Satterthwaite’s method). Post hoc analysis was
performed with a Tukey test for multiple comparisons. In
case of full SLE block during pharmacological intervention,
a two-sided, paired t-test was used to compare baseline and
wash-out. For comparison of independent groups, one-way
1https://inkscape.org
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FIGURE 1 | Flow diagram of used laboratory animals and experimental protocol. (A) Timeline of the experimental protocol. The duration of baseline, intervention,
and wash-out ranged between 40 and 60 min. (B) Flow diagram of all laboratory animals used in the study and their allocation to the different intervention groups.
Animals with too long preparation, failed SLE induction or incomplete dataset (∗mostly due to failure of recording before end of the experimental protocol) were
excluded from the study. ∗∗ In few cases, two slices from one animal were used and assigned to different groups. Numbers in lower panel therefore indicate number
of slices and in sum might exceed number of animals given above.
ANOVA with post hoc t-test (with Benjamini, Hochberg,
and Yekutieli adjustment of false discovery rate) was used.
In the latter case, post hoc t-tests were only calculated
between control and intervention groups. To assess the
influence of variations in parameters of SLEs at baseline,
Pearson’s correlations between the baseline data and the
relative effect of the intervention (intervention/baseline) were
calculated for SLE frequency and duration. Values of p < 0.05
were considered significant. All data are expressed as mean
value± standard deviation.
RESULTS
From a total of 116 animals used in the study, 86 were included
in the final analysis and 30 animals were excluded, mostly due to
incomplete recordings and failed SLE induction (Figure 1B). In
each experimental group, experiments were performed in tissue
from at least nine animals, except of two groups with full SLE
block (highest dosages of LAC and ZNS, respectively) in which
five animals per group were used. Due to technical reasons and
slice storage capacity, in most cases one in vitro recording per
animal was performed.
Electrophysiological Recordings
In the first step, we investigated the effects of AEDs on SLE
frequency. For an overview of representative recordings in all
groups, see Figure 2. In the control group (22 slices, 20 animals),
SLEs occurred at a frequency of 0.17 ± 0.03 min−1 1 h after
start of 4-AP application, then decreased to 0.15 ± 0.04 min−1
in the second hour and remained at this frequency in the last
hour of recording (second hour: p = 0.041; third hour: p = 0.035,
Figure 3A). Next, we focused on the effects of LAC, ZNS, and
LEV. The effect of the AEDs was independent of SLE frequency
and duration at baseline, as there was no significant correlation
with the relative changes of these parameters during intervention
(tested for LAC 33 µM, ZNS 100 µM, and LEV 100 µM;
non-significant correlation coefficients not shown). In case of
LAC, all investigated concentrations reduced SLE frequency. In
contrast to control experiments in which frequency reduction
prevailed in the wash-out phase, the effect of LAC was reversible
after wash-out. The effect was also dose-dependent such that
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FIGURE 2 | Representative local field potential recordings of control and all intervention groups. Each trace shows a complete recording of the local field potential in
EC beginning with the wash-in of 4-AP. The grayish box marks the time window of the intervention with the AED. Note the complete SLE block with LAC 100 and
ZNS 300 µM. Though interictal like events were not analyzed systematically, one can clearly see different patterns of their representation. In some recordings, the
interictal like events seem to increase during intervention (e.g., LAC 100 µM), in some no visible changes can be observed (e.g., ZNS 100 µM) and in others their
frequency seems to be reduced (ZNS 300 µM). Overall there was no obvious clear effect. For better visualization, slow drifts were removed.
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FIGURE 3 | Modulation of the SLE frequency by different AEDs. The scatterplots represent SLE frequency for individual recordings and the superimposed line
graphs show the mean ± standard deviation for control (A) and the AED (B–D) groups. Within the groups, except for LEV 33 µM, SLE frequency significantly
decreased from baseline to the end of the intervention (second hour for the control group). Asterisks indicate significant decrease of SLE frequency during and in
some cases after intervention compared to baseline (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
SLEs were completely blocked when 100 µM LAC was applied
(baseline vs. intervention; 10 µM: 13 slices, p = 0.025; 33 µM:
10 slices, p = 0.005; 100 µM: 5 slices, p < 0.001; Figure 3B).
Similar effects were observed upon application of ZNS. Again,
reduction of SLE frequency was dose-dependent, and 300 µM
ZNS suppressed SLEs completely (baseline vs. intervention;
33µM: 10 slices, p< 0.001; 100µM: 13 slices, p< 0.001; 300µM:
5 slices, p < 0.001; Figure 3C). However, unlike in the LAC
group, SLE frequency did not recover completely after wash-out
(baseline vs. wash-out; 33 µM: p = 0.036; 100 µM: p = 0.027;
300 µM: p = 0.001).
Compared to LAC and ZNS, the effect of LEV on SLE
frequency was markedly smaller. In the lowest concentration
(33 µM), no significant effect was observed (baseline vs.
intervention: 0.16± 0.02 vs. 0.13± 0.04 SLE/min, p = 0.053, nine
slices; Figure 3D). At 100 and 300 µM, LEV application resulted
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in a reduction of SLE frequency (baseline vs. intervention;
100 µM: 11 slices, p = 0.006; 300 µM: 11 slices, p = 0.003;
Figure 3D), and a complete SLE block occurred only in two slices
(one slice in the 100 and 300 µM groups, respectively).
As stated above, we observed a time-dependent decrease of
SLE frequency in control slices. To account for this effect in those
experiments with AED application, we performed comparisons
of SLE frequency ratios (intervention or second hour of
control/baseline) between investigated groups. As expected from
intragroup analyses (Figure 3), ratio of SLE frequency was lower
after application of LAC (33 and 100 µM) and ZNS (100 and
300 µM) when compared to control (control: 0.90; LAC 33 µM:
0.54, p = 0.001; LAC 100 µM: 0, p < 0.001; ZNS 100 µM: 0.56,
p = 0.001; ZNS 300µM: 0, p< 0.001; Figure 4). In the LEV group,
only the highest concentration of 300 µM was different from
control (LEV 300 µM: 0.66 vs. 0.90, p = 0.034). Analysis of the
responder rate confirmed that LAC and ZNS displayed a strong
and dose-dependent effect on 4-AP-induced SLEs (Figure 4). For
a summary of all parameters with regard to SLE frequency, see
Supplementary Table S1.
In addition to SLE frequency, we also analyzed SLE duration
and the amplitude of the DC shift in all groups except in those
with total SLE block (LAC 100 µM, ZNS 300 µM).
In the control group, SLE duration did not change over
time (baseline: 53.3 s, after second hour: 56.9 s, after third
hour: 52.5 s; F(2,42) = 2.98, p = 0.061). Overall, drug effects
on SLE duration were occasional and not concentration-
dependent: ZNS (33 µM) increased SLE duration in a reversible
manner (baseline: 60.1 s, intervention: 68.1 s, p = 0.040;
wash-out: 60.6 s, p = 0.986), but the effect was not different
from control (p = 0.544) when comparing effect ratios (see
above). Application of LEV (300 µM) resulted in a continuous
decrease of SLE duration (baseline: 58.2 s, intervention: 46.2 s,
p = 0.031; wash-out: 37.7 s, p < 0.001), which was the only
effect different from control (p = 0.015) when comparing
effect ratios. The remaining groups showed no alterations
of SLE duration. The amplitude of the DC shift decreased
over time in the control group (baseline: 1.64 mV, second
hour: 1.52 mV, p = 0.025; third hour: 1.43 mV, p < 0.001)
but also when LAC 33 µM, ZNS 33 µM, or LEV 300 µM
were applied. These effects were not different from controls
(F(7,85) = 1.81, p = 0.096). For a summary of all parameters
of SLE duration and amplitude of the DC shift, see also
Supplementary Table S1.
Intrinsic Optical Signals
Intrinsic optical signals was acquired in order to investigate drug
effects on SLE onset, intensity, and propagation. All experiments
except those with SLE block upon AED application (LAC
100 µM, ZNS 300 µM) were included. Analysis was performed
separately in four predefined subregions (SUB, EC, PC, and TC,
see Figure 5A). In the majority of slices, SLE onset was located in
the EC and TC areas as described before (Weissinger et al., 2000,
2017; Figure 5A).
In the control group, IOS intensity (1T/T) remained
unchanged in all investigated regions (Supplementary Table S2).
Also after AED application, 1T/T did not change in most
regions except the SUB. Here, LAC (10 µM, 33 µM) and
ZNS (100 µM), but not LEV, markedly reduced 1T/T (LAC
10 µM: baseline: 1.43%, intervention: 1.13%, p = 0.001; LAC
33 µM: baseline: 1.10%, intervention: 0.38%, p < 0.001; ZNS:
baseline: 1.17%, intervention: 0.78%, p = 0.016; Figures 5B,C).
Intergroup analysis revealed differences in the intervention-to-
baseline ratio of 1T/T in the SUB between drug and control
groups (F(7,84) = 2.82; p = 0.011), however, significance level was
not reached in post hoc tests.
The area affected by the SLE was calculated for each region
separately and expressed as percentage of the investigated
region. In the control group, no differences in the SLE area
between successive time points were detectable. Similar to
1T/T, application of LAC (10 µM, 33 µM) or ZNS (100 µM)
resulted in a reduction of the SLE area exclusively in the SUB
(LAC 10 µM: baseline: 70.9%, intervention: 61.7%, p = 0.016;
LAC 33 µM: baseline: 58.9%, intervention: 37.8%, p < 0.001;
ZNS 100 µM: baseline: 51.3%, intervention: 40.2%, p = 0.008;
Figures 5C1,C2). In contrast, application of LEV did not affect
the SUB but reduced SLE area in the TC when applied at a
concentration of 300 µM (baseline: 54.8%, intervention 37.6%,
p = 0.025; Figure 5C3). Intergroup analyses detected differences
between drug and control groups in the SUB (p = 0.005),
which, however, could not be confirmed in post hoc tests
(Supplementary Table S3). For a summary of all investigated IOS
parameters, see Supplementary Tables S2, S3.
DISCUSSION
In the present study, we assessed antiepileptic effects of selected
new-generation AEDs with distinct mechanisms of action in
the 4-AP model of acute seizures in vitro. We demonstrated
that in addition to standard AEDs tested previously, the 4-
AP model in vitro was also able to detect antiepileptic effects
in new-generation AEDs (LAC, ZNS, LEV) at concentrations
approximate to those observed in patients (Schulz et al., 2012).
Simultaneous electrophysiological and optical recordings in
acute hippocampal slices revealed SLE frequency as the most
sensitive parameter. While all applied AEDs induced a robust
decrease of SLE frequency, the effect on SLE duration and
amplitude of the DC shift was small and not compelling and
the IOS effects were region- and compound-selective. In contrast
to our data, Lees et al. (2006) reported a reduced duration and
a diminished DC shift of SLEs induced by 4-AP in the visual
cortex after wash-in of LAC (2006), but only at a high dose
(100 µM) that completely blocked SLEs in our experiments. The
results suggest that AED sensitivity might vary across distinct
cortical regions. With regard to LEV, our observations are in
line with previous in vivo studies demonstrating reduced SLE
frequency but not altered SLE duration (Glien et al., 2002;
Lévesque et al., 2015).
Beside SLEs, we observed interictal like events in most of the
recordings, which are thought to represent interictal epileptiform
activity in vivo. As the clinical relevance and the diagnostic value
of interictal activity are discussed controversially (Usui et al.,
2008; Jacobs et al., 2010), in this in vitro study, we renounced to
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FIGURE 4 | Modulation of SLE frequency by AEDs and responder rates. The upper diagram shows univariate scatterplots of the SLE frequency ratios
(intervention/baseline). Compared to the control group, SLE frequency ratio is significantly decreased (indicated by asterisks) in the medium concentration of LAC
and ZNS and in the highest concentration of all three AEDs (LAC, ZNS, and LEV). The responder rate (bar graphs in the lower diagram) defined as reduction of SLEs
during intervention of at least 50% compared to baseline indicates a stronger anticonvulsant effect of LAC and ZNS vs. LEV.
systematically analyze interictal like events and focused on the
thorough analysis of SLEs.
Of note, the investigated new-generation AEDs primarily did
not modulate other SLE properties than frequency and thus
rather seem to affect their induction but not maintenance of ictal
activity. Importantly, gap junctions are involved in the control
of seizure duration in vivo (Gajda et al., 2003), and none of the
applied AEDs has been described to modulate gap junctions.
While both LAC and ZNS displayed a robust and dose-
dependent antiepileptic effect and were capable of completely
blocking SLEs, the effect of LEV in this model was smaller. Still,
in contrast to lacking effects in the PTZ/MES models in vivo,
the 4-AP model in vitro was able to detect an antiepileptic effect
of LEV within the therapeutic concentration range albeit it was
rather small. A direct comparison of in vivo and in vitro drug
concentrations is always challenging, mainly because of different
mechanisms of drug uptake (blood-brain-barrier, permeability of
tissue, active transport). The AED concentrations chosen here
ranging from the lower limit to a maximum of 1.3–1.8 times
above the upper limit of the therapeutic range in humans (Schulz
et al., 2012). This is in accordance with a previous study that
suggested that the effective concentration in vivo and in vitro
might be in the same range (Heinemann et al., 1985).
In contrast to LAC and LEV, ZNS displayed an antiepileptic
effect that was persistent after wash-out of the substance. This
observation suggests that ZNS might induce long-lasting changes
in the intrinsic excitability that outlive the direct substance effect.
A possible explanation could be a long-lasting reduction in
intracellular pH induced by carbonic anhydrase inhibition (but
see Thöne et al., 2008).
As mentioned above, IOS effects were confined to specific
regions, i.e., LAC and ZNS reduced IOS intensity and the area
affected by the SLEs specifically in the SUB. IOS intensity was
calculated as mean per ROI, therefore reduction of the affected
area alone could have led to reduced calculated IOS intensity by
a higher pixel number of a given ROI not reaching detection
threshold. In conclusion, the observed reduced IOS intensity
might represent an effect of technical limitations (ROI size,
video resolution) rather than a real reduction. Irrespective of
that, the specific effect in the SUB is intriguing. Previous studies
underpinned the crucial role of the SUB in the induction of
SLEs in the 4-AP model (Benini and Avoli, 2005; Herrington
et al., 2015), which might explain the high sensitivity of this
area to LAC and ZNS.
In vitro seizure models in brain slices offer the advantage
of performing several experiments in one animal and
simultaneously avoiding the animal burden produced by
in vivo seizure events. In our study, we performed 1–2 in vitro
experiments per animal, which seems rather low and was mostly
due to limited storage and recording capacities in our facility.
However, in case of larger technical capacities as often provided
in drug screening units, up to 10 experiments per animal seem to
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FIGURE 5 | Recordings of the IOS. For analysis of the onset zone, spread, and local intensity of the SLEs, the IOS was recorded simultaneously to local field
potentials. As described in previous studies, the SLEs started in different regions within the same slice. Note the relatively small area of the SUB. (A1) The
electrophysiological recording shows a representative SLE from the EC. After the onset with a sharp transient there is a tonic phase resting about 10 s. This goes
over into the clonic phase, which lasts about 50 s. (A2) The pictures show the color-coded IOS intensity over time during an SLE. In the upper row, the SLE starts in
the EC and then continuously spreads mainly to the PC and TC. In the lower row, the SLE starts in the PC and then spreads vice versa to the TC and EC. In the
SUB, LAC (B1,C1) and ZNS (B2,C2) reduce the IOS intensity and the size of the area the SLE is spreading to. The third AED, LEV, reduces the SLE area but not IOS
intensity in the TC (B3,C3). All effects are reversed at the end of the wash-out. Asterisks indicate significant decrease of IOS intensity or SLE area compared to
baseline (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
be a realistic estimate, which is determined mostly by biological
constraints, i.e., brain size of the investigated species.
Together with previous literature, our findings suggest
that the 4-AP model in vitro is sensitive for the detection
of antiepileptic properties across substances with various
mechanisms of action. This applies to standard AEDs (Fueta
and Avoli, 1992; D’Antuono et al., 2010), new-generation
AEDs (this work) as well as future potential antiepileptic
substances. Dóczi et al. (1999) demonstrated that AMPA receptor
antagonists can dose-dependently modulate the frequency and
duration of interictal discharges in the neocortex of adult
rats in the 4-AP model in vitro. However, there is currently
no study, which verifies these findings with the clinically
used AMPA receptor antagonist perampanel. Enhancement
of GABAergic inhibition by benzodiazepine derivatives was
effective against epileptiform activity (evoked epileptiform
burst activity, SLEs) in two independent studies in vitro
(Marinelli et al., 2000; Ridler et al., 2018), which is in
line with the involvement of GABAergic interneurons in
the synchronous activity during SLEs in the 4-AP model
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(Grosser et al., 2014). Finally, in cultured hippocampal neurons,
KCNQ potassium channel openers suppressed epileptiform
activity induced by 4-AP (Kobayashi et al., 2008). In the current
study we did not involve a negative control using a known
proconvulsant substance. For a possible screening tool of the
anticonvulsant properties, the detection of a negative effect
of the screened substances would be essential. Adding the
GABA-A receptor antagonist bicuculline to the 4-AP model
has been shown to make SLEs resistant against standard
anticonvulsant drugs like phenytoin, carbamazepine, valproic
acid, or phenobarbital (Brückner et al., 1999). Future studies
should test if this effect is consistent also with new-generation
anticonvulsant drugs.
As mentioned above, there are a number of relevant in vitro
models of acute seizures. Compared to these models, the 4-AP
model applied here offers the advantage of stable conditions
regarding SLE morphology and frequency over several hours,
low rate of spreading depolarizations, and ictal activity which
clearly can be distinguished from interictal discharges. In
contrast, the low Mg2+ model has a high occurrence rate
of spreading depolarizations, and the SLEs are not stable for
more than an hour (Mody et al., 1987). Furthermore, the SLEs
are often resistant to standard AEDs such as carbamazepine
and valproic acid. This might be advantageous if one is
looking for novel treatment options of pharmacoresistance,
but is a hindrance for exploratory screening (Dreier et al.,
1998; Dost and Rundfeldt, 2000; Arias and Bowlby, 2005).
The high K+ model also has a high rate of spreading
depolarizations, and in rats, the epileptiform discharges are very
variable with respect to morphology and frequency (Traynelis
and Dingledine, 1988). This disadvantage can be avoided by
using another species, such as mice (Lopantsev et al., 2009).
Thereby, depending on the aim of this study and the applied
substances, a proper choice of the chosen species might be
necessary. The GABA-A receptor antagonists gabazine and
picrotoxine convert hippocampal sharp wave-ripple-complexes
into recurrent epileptiform discharges (Behrens et al., 2007).
There is little data on the effects of AEDs or long-term stability
of the SLEs. Taken together, the 4-AP model seems to be
advantageous in terms of SLE induction and stability, however,
further studies are necessary for comparison of its potential with
other in vitro models.
A major limitation of acute seizure models in vivo and
in vitro is the lacking representation of epileptic conditions
occurring after epileptogenesis in neuronal networks. Therefore,
these models are not capable of representing features of the
drug-resistant brain. This might in part explain the failed
translation of findings from these animal models to patients
with epilepsy and in particular with drug-resistant epilepsy. In a
systematic screening approach designed to overcome this enigma,
a combination of both acute and chronic epilepsy models and
the use of translationally more relevant ex vivo human tissue
(e.g., from epilepsy surgery) is suggested. In this respect, the 4-
AP model in vitro might present as a possible candidate model
with high sensitivity to detect antiepileptic properties, which
could be included in an exploratory screening line. In this first
step, this would reduce the number of in vivo experiments.
However, following preselection, in vivo approaches might be
unavoidable in subsequent testing in chronic models of epilepsy
and pharmacoresistance.
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